Mr Sharma announced a further £84m in new funding "to help accelerate their work".
Moderna, a MA based company, developed the vaccination, and it prompts an immune response in the human body, "and was also found to be safe and well-tolerated in a small group of patients", the report said.
In all trial participants to date, the vaccine candidate led to seroconversion with binding antibody levels either at or above levels seen in convalescent sera.
"The UK will be first to get access", he added, noting it would also work to ensure the vaccine could be made available "to developing countries at the lowest possible cost".
In the study, six rhesus macaques were injected with a single dose of the vaccine called ChAdOx1 nCoV-19 28 days before being infected with SARS-CoV-2 and compared to three control animals that did not receive the vaccine.
Mary-Kate Olsen Files Emergency Divorce Petition
Mary-Kate Olsen and husband Olivier Sarkozy pictured together back in 2012, when they first started dating. She petitioned a NY court for an emergency divorce from estranged husband Olivier Sarkozy .
Business Secretary Alok Sharma announced yesterday evening that a global licensing deal had been signed between Oxford University and the pharma firm as part of a £130million plan to vaccinate half the United Kingdom population. In April, the U.S. Biomedical Advanced Research and Development Authority (BARDA) allocated up to $483 million for vaccine development.
"Today I can report six drugs have entered initial live clinical trials", he said.
"AstraZeneca is engaged with worldwide organisations.as well as governments around the world with the aim of delivering a safe, effective and globally accessible vaccine as quickly as possible", a spokesman told Reuters.
He told the Mirror: 'Everybody is moving ahead with the belief we'll have a vaccine by the end of the year. The favorable results do not prove the vaccine works but suggest that it would give patients a degree of immunity.
Mr Sharma said the Government has now committed more than a quarter of a billion pounds towards developing a vaccine in the UK.
"Slaoui's blatant financial conflicts of interest disqualify him for the role of vaccine czar, unless he commits immediately to global vaccine access conditions over the obvious profit interests of the corporation he serves", said Peter Maybarduk, director of the Access to Medicines Program at Public Citizen, a consumer advocacy group.